Lineage Cell Therapeutics (LCTX) announced the formation of a Scientific Advisory Board, SAB, to provide strategic counsel and insights into the development of Lineage’s novel cell transplant pipeline, built on the Company’s proprietary cell differentiation and expansion platform, AlloSCOPE. The founding member of the SAB is Joachim Fruebis, Ph.D. Additional SAB members are expected to be added throughout the remainder of the year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Cell Therapeutics management to meet with Craig-Hallum
- Lineage Cell Therapeutics price target raised to $4 from $3 at B. Riley
- Lineage Cell launches cell therapy program in corneal endothelial disease
- Lineage Therap Expands ATM Equity Offering Capacity
- Lineage Cell Therapeutics Extends Runway Amid R&D Surge